Searle & Co’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.14M | Buy |
88,705
+943
| +1% | +$24.7K | 0.48% | 53 |
|
|
2026
Q1 | $2.46M | Sell |
87,762
-2,657
| -3% | -$70.7K | 0.62% | 44 |
|
|
2025
Q4 | $2.25M | Sell |
90,419
-1,691
| -2% | -$42.6K | 0.58% | 45 |
|
|
2025
Q3 | $2.35M | Sell |
92,110
-709
| -0.8% | -$17.5K | 0.62% | 45 |
|
|
2025
Q2 | $2.25M | Sell |
92,819
-1,750
| -2% | -$40.8K | 0.64% | 46 |
|
|
2025
Q1 | $2.4M | Sell |
94,569
-2,591
| -3% | -$67.8K | 0.68% | 40 |
|
|
2024
Q4 | $2.58M | Buy |
97,160
+4,091
| +4% | +$111K | 0.74% | 39 |
|
|
2024
Q3 | $2.69M | Sell |
93,069
-18,628
| -17% | -$543K | 0.67% | 37 |
|
|
2024
Q2 | $3.13M | Buy |
111,697
+61,354
| +122% | +$1.69M | 0.73% | 35 |
|
|
2024
Q1 | $1.4M | Sell |
50,343
-7,000
| -12% | -$194K | 0.36% | 64 |
|
|
2023
Q4 | $1.65M | Sell |
57,343
-24,469
| -30% | -$740K | 0.45% | 55 |
|
|
2023
Q3 | $2.71M | Sell |
81,812
-1,254
| -2% | -$44.3K | 0.92% | 29 |
|
|
2023
Q2 | $3M | Sell |
83,066
-1,496
| -2% | -$58.2K | 0.93% | 29 |
|
|
2023
Q1 | $3.29M | Sell |
84,562
-1,600
| -2% | -$69.1K | 1.08% | 26 |
|
|
2022
Q4 | $4.41M | Hold |
86,162
| – | – | 1.51% | 18 |
|
|
2022
Q3 | $3.77M | Hold |
86,162
| – | – | 1.45% | 17 |
|
|
2022
Q2 | $4.52M | Hold |
86,162
| – | – | 1.78% | 13 |
|
|
2022
Q1 | $4.46M | Buy |
86,162
+1,700
| +2% | +$88.2K | 1.65% | 15 |
|
|
2021
Q4 | $4.99M | Buy |
84,462
+3,649
| +5% | +$181K | 1.81% | 11 |
|
|
2021
Q3 | $3.48M | Buy |
80,813
+500
| +0.6% | +$22.1K | 1.42% | 24 |
|
|
2021
Q2 | $3.15M | Sell |
80,313
-9,000
| -10% | -$350K | 1.29% | 26 |
|
|
2021
Q1 | $3.24M | Buy |
89,313
+9,000
| +11% | +$320K | 1.44% | 21 |
|
|
2020
Q4 | $2.96M | Sell |
80,313
-4,969
| -6% | -$182K | 1.42% | 22 |
|
|
2020
Q3 | $2.97M | Sell |
85,282
-6,061
| -7% | -$212K | 1.62% | 16 |
|
|
2020
Q2 | $2.83M | Sell |
91,343
-122
| -0.1% | -$4.14K | 1.64% | 17 |
|
|
2020
Q1 | $2.83M | Buy |
91,465
+8,432
| +10% | +$287K | 2.01% | 12 |
|
|
2019
Q4 | $3.09M | Buy |
83,033
+839
| +1% | +$29.9K | 1.7% | 17 |
|
|
2019
Q3 | $2.8M | Sell |
82,194
-839
| -1% | -$30.5K | 1.65% | 18 |
|
|
2019
Q2 | $3.41M | Hold |
83,033
| – | – | 2.08% | 14 |
|
|
2019
Q1 | $3.35M | Buy |
83,033
+744
| +0.9% | +$29.8K | 2.09% | 12 |
|
|
2018
Q4 | $3.41M | Sell |
82,289
-211
| -0.3% | -$8.76K | 2.4% | 7 |
|
|
2018
Q3 | $3.45M | Sell |
82,500
-105
| -0.1% | -$4.04K | 2.02% | 10 |
|
|
2018
Q2 | $2.84M | Hold |
82,605
| – | – | 1.8% | 14 |
|
|
2018
Q1 | $2.78M | Hold |
82,605
| – | – | 1.81% | 15 |
|
|
2017
Q4 | $2.84M | Buy |
82,605
+263
| +0.3% | +$8.97K | 1.78% | 15 |
|
|
2017
Q3 | $2.79M | Sell |
82,342
-527
| -0.6% | -$16.9K | 1.84% | 10 |
|
|
2017
Q2 | $2.64M | Sell |
82,869
-1,506
| -2% | -$47.5K | 1.81% | 10 |
|
|
2017
Q1 | $2.74M | Buy |
84,375
+40,579
| +93% | +$1.28M | 1.92% | 8 |
|
|
2016
Q4 | $1.35M | Buy |
43,796
+6,748
| +18% | +$206K | 1.12% | 33 |
|
|
2016
Q3 | $1.19M | Buy |
+37,048
| New | +$1.24M | 1.03% | 36 |
|
|
2016
Q2 | – | Sell |
-37,048
| Closed | -$1.06M | – | 78 |
|
|
2016
Q1 | $1.06M | Buy |
37,048
+2,761
| +8% | +$78.9K | 0.97% | 39 |
|
|
2015
Q4 | $1.04M | Sell |
34,287
-34,432
| -50% | -$1.08M | 1% | 40 |
|
|
2015
Q3 | $2.05M | Buy |
68,719
+34,678
| +102% | +$1.11M | 2.1% | 10 |
|
|
2015
Q2 | $1.08M | Sell |
34,041
-1
| -0% | -$33 | 0.9% | 37 |
|
|
2015
Q1 | $1.12M | Buy |
34,042
+1
| +0% | +$32 | 0.97% | 37 |
|
|
2014
Q4 | $1.01M | Buy |
+34,041
| New | +$976K | 0.85% | 38 |
|
Other funds holding PFE
Searle & Co's PFE Position: Q2 2026 in Review
Searle & Co increased its Pfizer (PFE) stake by 1.1% in Q2 2026, buying an estimated $24.7K and bringing the position to 88,705 shares worth $2.14M. The position accounts for 0.48% of the portfolio, ranked #53.
Searle & Co first reported a position in PFE in Q4 2014 and has held it in 46 quarters since. The position peaked at $4.99M in Q4 2021. 2,820 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Searle & Co held 88,705 shares of Pfizer worth $2.14M as of Q2 2026.
- Searle & Co bought 943 Pfizer shares in Q2 2026, an estimated $24.7K.
- Pfizer made up 0.48% of Searle & Co's portfolio in Q2 2026, its #53 holding.
- Searle & Co first reported a position in Pfizer in Q4 2014 and has held it in 46 quarters since.
- Searle & Co's Pfizer position peaked at $4.99M in Q4 2021.
- 2,820 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Searle & Co's 13F filing for Q2 2026, filed 27 Jul 2026.